Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 80

1.

Modeling the Effects of Multiple Myeloma on Kidney Function.

Walk JC, Ayati BP, Holstein SA.

Sci Rep. 2019 Feb 11;9(1):1726. doi: 10.1038/s41598-018-38129-7.

2.

Determination of Minimal Residual Disease in Multiple Myeloma: Does It Matter?

Kothari S, Hillengass J, McCarthy PL, Holstein SA.

Curr Hematol Malig Rep. 2019 Feb;14(1):39-46. doi: 10.1007/s11899-019-0497-7. Review.

PMID:
30671912
3.

Should Overall Survival Remain an Endpoint for Multiple Myeloma Trials?

Holstein SA, Suman VJ, McCarthy PL.

Curr Hematol Malig Rep. 2019 Feb;14(1):31-38. doi: 10.1007/s11899-019-0495-9. Review.

PMID:
30661162
4.

Commentary on "Is posttransplant lenalidomide the standard-of-care after an autotransplant for plasma cell myeloma" by Giovanni Barosi and Robert Peter Gale.

Holstein SA, Suman VJ, McCarthy PL.

Leukemia. 2019 Feb;33(2):565-566. doi: 10.1038/s41375-018-0359-7. Epub 2019 Jan 11. No abstract available.

PMID:
30635635
5.

Tropolone-induced effects on the unfolded protein response pathway and apoptosis in multiple myeloma cells are dependent on iron.

Haney SL, Varney ML, Safranek HR, Chhonker YS, G-Dayanandan N, Talmon G, Murry DJ, Wiemer AJ, Wright DL, Holstein SA.

Leuk Res. 2019 Feb;77:17-27. doi: 10.1016/j.leukres.2018.12.007. Epub 2018 Dec 21.

PMID:
30612055
6.

Simultaneous Quantitation of Isoprenoid Pyrophosphates in Plasma and Cancer Cells Using LC-MS/MS.

Chhonker YS, Haney SL, Bala V, Holstein SA, Murry DJ.

Molecules. 2018 Dec 11;23(12). pii: E3275. doi: 10.3390/molecules23123275.

7.

Summary of the Second Annual BMT CTN Myeloma Intergroup Workshop on Minimal Residual Disease and Immune Profiling.

Holstein SA, Ye JC, Howard A, Bhutani M, Gormley N, Hahn T, Hillengass J, Krishnan A, Landgren CO, Munshi NC, Oliva S, Owen RG, Pasquini MC, Puig N, Weinhold N, Weisel K, McCarthy PL.

Biol Blood Marrow Transplant. 2018 Nov 5. pii: S1083-8791(18)30694-3. doi: 10.1016/j.bbmt.2018.11.001. [Epub ahead of print]

PMID:
30408566
8.

Maintenance Treatment and Survival in Patients With Myeloma: A Systematic Review and Network Meta-analysis.

Gay F, Jackson G, Rosiñol L, Holstein SA, Moreau P, Spada S, Davies F, Lahuerta JJ, Leleu X, Bringhen S, Evangelista A, Hulin C, Panzani U, Cairns DA, Di Raimondo F, Macro M, Liberati AM, Pawlyn C, Offidani M, Spencer A, Hájek R, Terpos E, Morgan GJ, Bladé J, Sonneveld P, San-Miguel J, McCarthy PL, Ludwig H, Boccadoro M, Mateos MV, Attal M.

JAMA Oncol. 2018 Oct 1;4(10):1389-1397. doi: 10.1001/jamaoncol.2018.2961.

PMID:
30098165
9.

Methods to prevent and treat relapse after hematopoietic stem cell transplantation with tyrosine kinase inhibitors, immunomodulating drugs, deacetylase inhibitors, and hypomethylating agents.

Chen YB, McCarthy PL, Hahn T, Holstein SA, Ueda M, Kröger N, Bishop M, de Lima M.

Bone Marrow Transplant. 2018 Jul 23. doi: 10.1038/s41409-018-0269-3. [Epub ahead of print] Review.

PMID:
30038353
10.

Update on the role of lenalidomide in patients with multiple myeloma.

Holstein SA, Suman VJ, McCarthy PL.

Ther Adv Hematol. 2018 Jul;9(7):175-190. doi: 10.1177/2040620718775629. Epub 2018 May 26. Review.

11.

Present and Future of Immunotherapy in the Management of Multiple Myeloma.

Baljevic M, Holstein SA.

J Oncol Pract. 2018 Jul;14(7):403-410. doi: 10.1200/JOP.18.00111.

PMID:
29996070
12.

Next-Generation Drugs Targeting the Cereblon Ubiquitin Ligase.

Holstein SA, Hillengass J, McCarthy PL.

J Clin Oncol. 2018 Jul 10;36(20):2101-2104. doi: 10.1200/JCO.2018.77.9637. Epub 2018 May 1. No abstract available.

PMID:
29715055
13.

Preclinical investigation of a potent geranylgeranyl diphosphate synthase inhibitor.

Haney SL, Chhonker YS, Varney ML, Talmon G, Murry DJ, Holstein SA.

Invest New Drugs. 2018 Oct;36(5):810-818. doi: 10.1007/s10637-018-0571-3. Epub 2018 Mar 2.

PMID:
29497895
14.

Quantitative determination of a potent geranylgeranyl diphosphate synthase inhibitor using LC-MS/MS: Derivatization and application.

Chhonker YS, Haney SL, Matthiesen RA, Wiemer DF, Holstein SA, Murry DJ.

J Pharm Biomed Anal. 2018 May 10;153:22-28. doi: 10.1016/j.jpba.2018.02.010. Epub 2018 Feb 6.

PMID:
29455093
15.

Immune signatures associated with improved progression-free and overall survival for myeloma patients treated with AHSCT.

Ho CM, McCarthy PL, Wallace PK, Zhang Y, Fora A, Mellors P, Tario JD, McCarthy BLS, Chen GL, Holstein SA, Balderman SR, Cao X, Paiva B, Hahn T.

Blood Adv. 2017 Jun 20;1(15):1056-1066. doi: 10.1182/bloodadvances.2017005447. eCollection 2017 Jun 27.

16.

NCCN Guidelines Insights: Multiple Myeloma, Version 3.2018.

Kumar SK, Callander NS, Alsina M, Atanackovic D, Biermann JS, Castillo J, Chandler JC, Costello C, Faiman M, Fung HC, Godby K, Hofmeister C, Holmberg L, Holstein S, Huff CA, Kang Y, Kassim A, Liedtke M, Malek E, Martin T, Neppalli VT, Omel J, Raje N, Singhal S, Somlo G, Stockerl-Goldstein K, Weber D, Yahalom J, Kumar R, Shead DA.

J Natl Compr Canc Netw. 2018 Jan;16(1):11-20. doi: 10.6004/jnccn.2018.0002.

PMID:
29295877
17.

α-Methylation enhances the potency of isoprenoid triazole bisphosphonates as geranylgeranyl diphosphate synthase inhibitors.

Matthiesen RA, Varney ML, Xu PC, Rier AS, Wiemer DF, Holstein SA.

Bioorg Med Chem. 2018 Jan 15;26(2):376-385. doi: 10.1016/j.bmc.2017.10.023. Epub 2017 Oct 19.

18.

BMT CTN Myeloma Intergroup Workshop on Minimal Residual Disease and Immune Profiling: Summary and Recommendations from the Organizing Committee.

Holstein SA, Avet-Loiseau H, Hahn T, Ho CM, Lohr JG, Munshi NC, Paiva B, Pasquini MC, Tario JD Jr, Usmani SZ, Wallace PK, Weisel K, McCarthy PL.

Biol Blood Marrow Transplant. 2018 Apr;24(4):641-648. doi: 10.1016/j.bbmt.2017.12.774. Epub 2017 Dec 11. Review.

PMID:
29242112
19.

Lenalidomide in combination or alone as maintenance therapy following autologous stem cell transplant in patients with multiple myeloma: a review of options for and against.

Richardson PG, Holstein SA, Schlossman RL, Anderson KC, Attal M, McCarthy PL.

Expert Opin Pharmacother. 2017 Dec;18(18):1975-1985. doi: 10.1080/14656566.2017.1409207. Epub 2017 Dec 1. Review.

PMID:
29172855
20.

Novel tropolones induce the unfolded protein response pathway and apoptosis in multiple myeloma cells.

Haney SL, Allen C, Varney ML, Dykstra KM, Falcone ER, Colligan SH, Hu Q, Aldridge AM, Wright DL, Wiemer AJ, Holstein SA.

Oncotarget. 2017 Jun 16;8(44):76085-76098. doi: 10.18632/oncotarget.18543. eCollection 2017 Sep 29.

21.

Updated analysis of CALGB (Alliance) 100104 assessing lenalidomide versus placebo maintenance after single autologous stem-cell transplantation for multiple myeloma: a randomised, double-blind, phase 3 trial.

Holstein SA, Jung SH, Richardson PG, Hofmeister CC, Hurd DD, Hassoun H, Giralt S, Stadtmauer EA, Weisdorf DJ, Vij R, Moreb JS, Callander NS, van Besien K, Gentile TG, Isola L, Maziarz RT, Bashey A, Landau H, Martin T, Qazilbash MH, Rodriguez C, McClune B, Schlossman RL, Smith SE, Hars V, Owzar K, Jiang C, Boyd M, Schultz C, Wilson M, Hari P, Pasquini MC, Horowitz MM, Shea TC, Devine SM, Linker C, Anderson KC, McCarthy PL.

Lancet Haematol. 2017 Sep;4(9):e431-e442. doi: 10.1016/S2352-3026(17)30140-0. Epub 2017 Aug 17. Erratum in: Lancet Haematol. 2018 Aug;5(8):e332. Erratum in: Lancet Haematol. 2018 Dec;5(12):e608.

22.

Lenalidomide Maintenance After Autologous Stem-Cell Transplantation in Newly Diagnosed Multiple Myeloma: A Meta-Analysis.

McCarthy PL, Holstein SA, Petrucci MT, Richardson PG, Hulin C, Tosi P, Bringhen S, Musto P, Anderson KC, Caillot D, Gay F, Moreau P, Marit G, Jung SH, Yu Z, Winograd B, Knight RD, Palumbo A, Attal M.

J Clin Oncol. 2017 Oct 10;35(29):3279-3289. doi: 10.1200/JCO.2017.72.6679. Epub 2017 Jul 25.

23.

Comparison of the adolescent and adult mouse prefrontal cortex proteome.

Agoglia AE, Holstein SE, Small AT, Spanos M, Burrus BM, Hodge CW.

PLoS One. 2017 Jun 1;12(6):e0178391. doi: 10.1371/journal.pone.0178391. eCollection 2017.

24.

Recent Advances in the Development of Mammalian Geranylgeranyl Diphosphate Synthase Inhibitors.

Haney SL, Wills VS, Wiemer DF, Holstein SA.

Molecules. 2017 May 27;22(6). pii: E886. doi: 10.3390/molecules22060886. Review.

25.

An Update on Tumors of the Lacrimal Gland.

Andreasen S, Esmaeli B, Holstein SL, Mikkelsen LH, Rasmussen PK, Heegaard S.

Asia Pac J Ophthalmol (Phila). 2017 Mar-Apr;6(2):159-172. doi: 10.22608/APO.201707. Review.

26.

Bishomoisoprenoid triazole bisphosphonates as inhibitors of geranylgeranyl diphosphate synthase.

Wills VS, Metzger JI, Allen C, Varney ML, Wiemer DF, Holstein SA.

Bioorg Med Chem. 2017 Apr 15;25(8):2437-2444. doi: 10.1016/j.bmc.2017.02.066. Epub 2017 Mar 4.

27.

Immunomodulatory Drugs in Multiple Myeloma: Mechanisms of Action and Clinical Experience.

Holstein SA, McCarthy PL.

Drugs. 2017 Apr;77(5):505-520. doi: 10.1007/s40265-017-0689-1. Review.

28.

Multiple Myeloma, Version 3.2017, NCCN Clinical Practice Guidelines in Oncology.

Kumar SK, Callander NS, Alsina M, Atanackovic D, Biermann JS, Chandler JC, Costello C, Faiman M, Fung HC, Gasparetto C, Godby K, Hofmeister C, Holmberg L, Holstein S, Huff CA, Kassim A, Liedtke M, Martin T, Omel J, Raje N, Reu FJ, Singhal S, Somlo G, Stockerl-Goldstein K, Treon SP, Weber D, Yahalom J, Shead DA, Kumar R.

J Natl Compr Canc Netw. 2017 Feb;15(2):230-269.

PMID:
28188192
29.

Olefin Isomers of a Triazole Bisphosphonate Synergistically Inhibit Geranylgeranyl Diphosphate Synthase.

Allen C, Kortagere S, Tong H, Matthiesen RA, Metzger JI, Wiemer DF, Holstein SA.

Mol Pharmacol. 2017 Mar;91(3):229-236. doi: 10.1124/mol.116.107326. Epub 2017 Jan 5.

30.

Phase 2 study of tabalumab, a human anti-B-cell activating factor antibody, with bortezomib and dexamethasone in patients with previously treated multiple myeloma.

Raje NS, Moreau P, Terpos E, Benboubker L, Grząśko N, Holstein SA, Oriol A, Huang SY, Beksac M, Kuliczkowski K, Tai DF, Wooldridge JE, Conti I, Kaiser CJ, Nguyen TS, Cronier DM, Palumbo A.

Br J Haematol. 2017 Mar;176(5):783-795. doi: 10.1111/bjh.14483. Epub 2016 Dec 22.

PMID:
28005265
31.

Role of stem cell transplant and maintenance therapy in plasma cell disorders.

McCarthy PL, Holstein SA.

Hematology Am Soc Hematol Educ Program. 2016 Dec 2;2016(1):504-511. Review.

32.

Novel α-substituted tropolones promote potent and selective caspase-dependent leukemia cell apoptosis.

Li J, Falcone ER, Holstein SA, Anderson AC, Wright DL, Wiemer AJ.

Pharmacol Res. 2016 Nov;113(Pt A):438-448. doi: 10.1016/j.phrs.2016.09.020. Epub 2016 Sep 20.

33.

Stereoselective Synthesis of Homoneryl and Homogeranyl Triazole Bisphosphonates.

Matthiesen RA, Wills VS, Metzger JI, Holstein SA, Wiemer DF.

J Org Chem. 2016 Oct 7;81(19):9438-9442. Epub 2016 Sep 20.

34.

Anaplastic Multiple Myeloma: An Aggressive Variant With a Poor Response to Novel Therapies.

Ammannagari N, Celotto K, Neppalli V, Lee K, Holstein SA.

Clin Lymphoma Myeloma Leuk. 2016 Sep;16(9):e129-e131. doi: 10.1016/j.clml.2016.06.008. Epub 2016 Jun 8. No abstract available.

PMID:
27375159
35.

Improved survival with salvage autologous stem-cell transplantation in myeloma.

Holstein SA, McCarthy PL.

Lancet Haematol. 2016 Jul;3(7):e306-7. doi: 10.1016/S2352-3026(16)30058-8. No abstract available.

PMID:
27374462
36.

A new motif for inhibitors of geranylgeranyl diphosphate synthase.

Foust BJ, Allen C, Holstein SA, Wiemer DF.

Bioorg Med Chem. 2016 Aug 15;24(16):3734-41. doi: 10.1016/j.bmc.2016.06.019. Epub 2016 Jun 10.

37.

Oral Ixazomib, Lenalidomide, and Dexamethasone for Multiple Myeloma.

Moreau P, Masszi T, Grzasko N, Bahlis NJ, Hansson M, Pour L, Sandhu I, Ganly P, Baker BW, Jackson SR, Stoppa AM, Simpson DR, Gimsing P, Palumbo A, Garderet L, Cavo M, Kumar S, Touzeau C, Buadi FK, Laubach JP, Berg DT, Lin J, Di Bacco A, Hui AM, van de Velde H, Richardson PG; TOURMALINE-MM1 Study Group.

N Engl J Med. 2016 Apr 28;374(17):1621-34. doi: 10.1056/NEJMoa1516282.

38.

NCCN Guidelines Insights: Multiple Myeloma, Version 3.2016.

Anderson KC, Alsina M, Atanackovic D, Biermann JS, Chandler JC, Costello C, Djulbegovic B, Fung HC, Gasparetto C, Godby K, Hofmeister C, Holmberg L, Holstein S, Huff CA, Kassim A, Krishnan AY, Kumar SK, Liedtke M, Lunning M, Raje N, Reu FJ, Singhal S, Somlo G, Stockerl-Goldstein K, Treon SP, Weber D, Yahalom J, Shead DA, Kumar R.

J Natl Compr Canc Netw. 2016 Apr;14(4):389-400.

39.

Stereocontrolled regeneration of olefins from epoxides.

Wills VS, Zhou X, Allen C, Holstein SA, Wiemer DF.

Tetrahedron Lett. 2016 Mar 23;57(12):1335-1337.

40.
41.

Cannabinoid CB1 receptor inhibition blunts adolescent-typical increased binge alcohol and sucrose consumption in male C57BL/6J mice.

Agoglia AE, Holstein SE, Eastman VR, Hodge CW.

Pharmacol Biochem Behav. 2016 Apr;143:11-7. doi: 10.1016/j.pbb.2016.01.009. Epub 2016 Jan 19.

42.

Potent Triazole Bisphosphonate Inhibitor of Geranylgeranyl Diphosphate Synthase.

Wills VS, Allen C, Holstein SA, Wiemer DF.

ACS Med Chem Lett. 2015 Oct 28;6(12):1195-8. doi: 10.1021/acsmedchemlett.5b00334. eCollection 2015 Dec 10.

43.

Continued role for ASCT in multiple myeloma.

McCarthy PL, Holstein SA.

Lancet Oncol. 2015 Dec;16(16):1571-3. doi: 10.1016/S1470-2045(15)00457-X. Epub 2015 Nov 17. No abstract available.

PMID:
26596669
44.

Mechanisms for autophagy modulation by isoprenoid biosynthetic pathway inhibitors in multiple myeloma cells.

Dykstra KM, Allen C, Born EJ, Tong H, Holstein SA.

Oncotarget. 2015 Dec 8;6(39):41535-49. doi: 10.18632/oncotarget.6365.

45.

Multiple Myeloma, Version 2.2016: Clinical Practice Guidelines in Oncology.

Anderson KC, Alsina M, Atanackovic D, Biermann JS, Chandler JC, Costello C, Djulbegovic B, Fung HC, Gasparetto C, Godby K, Hofmeister C, Holmberg L, Holstein S, Huff CA, Kassim A, Krishnan AY, Kumar SK, Liedtke M, Lunning M, Raje N, Singhal S, Smith C, Somlo G, Stockerl-Goldstein K, Treon SP, Weber D, Yahalom J, Shead DA, Kumar R; National Comprehensive Cancer Network.

J Natl Compr Canc Netw. 2015 Nov;13(11):1398-435.

46.

American Society of Blood and Marrow Transplantation, European Society of Blood and Marrow Transplantation, Blood and Marrow Transplant Clinical Trials Network, and International Myeloma Working Group Consensus Conference on Salvage Hematopoietic Cell Transplantation in Patients with Relapsed Multiple Myeloma.

Giralt S, Garderet L, Durie B, Cook G, Gahrton G, Bruno B, Hari P, Lokhorst H, McCarthy P, Krishnan A, Sonneveld P, Goldschmidt H, Jagannath S, Barlogie B, Mateos M, Gimsing P, Sezer O, Mikhael J, Lu J, Dimopoulos M, Mazumder A, Palumbo A, Abonour R, Anderson K, Attal M, Blade J, Bird J, Cavo M, Comenzo R, de la Rubia J, Einsele H, Garcia-Sanz R, Hillengass J, Holstein S, Johnsen HE, Joshua D, Koehne G, Kumar S, Kyle R, Leleu X, Lonial S, Ludwig H, Nahi H, Nooka A, Orlowski R, Rajkumar V, Reiman A, Richardson P, Riva E, San Miguel J, Turreson I, Usmani S, Vesole D, Bensinger W, Qazilbash M, Efebera Y, Mohty M, Gasparreto C, Gajewski J, LeMaistre CF, Bredeson C, Moreau P, Pasquini M, Kroeger N, Stadtmauer E.

Biol Blood Marrow Transplant. 2015 Dec;21(12):2039-2051. doi: 10.1016/j.bbmt.2015.09.016. Epub 2015 Sep 30.

47.

CaMKIIα-GluA1 Activity Underlies Vulnerability to Adolescent Binge Alcohol Drinking.

Agoglia AE, Holstein SE, Reid G, Hodge CW.

Alcohol Clin Exp Res. 2015 Sep;39(9):1680-90. doi: 10.1111/acer.12819. Epub 2015 Aug 6.

48.

N-Oxide derivatives of 3-(3-pyridyl)-2-phosphonopropanoic acids as potential inhibitors of Rab geranylgeranylation.

Zhou X, Born EJ, Allen C, Holstein SA, Wiemer DF.

Bioorg Med Chem Lett. 2015 Jun 1;25(11):2331-4. doi: 10.1016/j.bmcl.2015.04.021. Epub 2015 Apr 17.

49.

Teaching science writing in an introductory lab course.

Holstein SE, Mickley Steinmetz KR, Miles JD.

J Undergrad Neurosci Educ. 2015 Mar 15;13(2):A101-9. eCollection 2015 Spring.

50.

Alcohol alters the activation of ERK1/2, a functional regulator of binge alcohol drinking in adult C57BL/6J mice.

Agoglia AE, Sharko AC, Psilos KE, Holstein SE, Reid GT, Hodge CW.

Alcohol Clin Exp Res. 2015 Mar;39(3):463-75. doi: 10.1111/acer.12645. Epub 2015 Feb 19.

Supplemental Content

Loading ...
Support Center